Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison
Oral semaglutide causes substantially fewer gastrointestinal side effects than an alternative weight-loss drug, though head-to-head comparison data are limited.
In an indirect treatment comparison (not a head-to-head trial), oral semaglutide 25mg shows statistically greater weight loss (-3.2% body weight) and substantially better tolerability than orforglipron 36mg, with 13.9-fold lower odds of discontinuing due to GI adverse events. The results are hypothesis-generating for prescribers choosing between oral GLP-1 options but should be interpreted cautiously given methodological limitations of indirect comparisons and Novo Nordisk sponsorship.
What the study was
- Study design
- Population-adjusted indirect treatment comparison (anchored ITC); not a head-to-head RCT
- Population
- Adults with overweight/obesity without diabetes; OASIS 4 vs ATTAIN-1 trial populations
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Diabetes, Obesity and Metabolism
Why it surfaced
Topically relevant comparison of two emerging oral GLP-1 agents; ITC methodology limits causal inference; Novo Nordisk funding creates commercial bias concern; no head-to-head RCT data available.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.